Sjögren's syndrome: Diagnosis and therapeutic challenges in the elderly

Drugs and Aging

Volumn 25, Issue 1, 2008, Pages 19-33

  Ng, Kristine P ^a   Isenberg, David A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Windeyer Institute   (United Kingdom)

Author keywords

Artificial tears; Cevimeline, therapeutic use; Ciclosporin, therapeutic use; Cyclophosphamide, therapeutic use; Disease modifying antirheumatics, therapeutic use; Epratuzumab, therapeutic use; Etanercept, therapeutic use; Hydroxychloroquine, therapeutic use

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CEVIMELINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EPRATUZUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LA ANTIBODY; LIQUIFILM; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; POLYVINYL ALCOHOL; PREDNISOLONE; RITUXIMAB; RO ANTIBODY; TEARS NATURALE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGED; AUTOIMMUNE DISEASE; COMORBIDITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; KIDNEY DISEASE; LABORATORY DIAGNOSIS; LUNG DISEASE; LYMPHOMA; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND BIOPSY; SALIVARY GLAND DISEASE; SIDE EFFECT; SJOEGREN SYNDROME; SWEATING; UPPER RESPIRATORY TRACT; UROGENITAL TRACT DISEASE; VASCULITIS; XEROSTOMIA;

EID: 38049058736     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825010-00003     Document Type: Review

References (120)

1. Manthorpe R, Asmussen K, Oxholm P. Primary Sjogren's syndrome: diagnostic criteria, clinical features and disease activity. J Rheumatol Suppl 1997 Sep; 50: 8-11
2. Sanchez-Guerrero J, Perez-Dosal MR, Cardenas-Velazquez F, et al. Prevalence of Sjogren's syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology (Oxford) 2005 Feb; 44 (2): 235-40
3. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006 Feb; 45 (2): 187-91
4. Drosos AA, Andonopoulos AP, Costopoulos JS, et al. Prevalence of primary Sjogren's syndrome in an elderly population. Br J Rheumatol 1988 Apr; 27 (2): 123-7
5. Whaley K, Williamson J, Wilson T, et al. Sjogren's syndrome and autoimmunity in a geriatric population. Age Ageing 1972 Nov; 1: 197-206
6. Tapinos NI, Polihronis M, Tzioufas AG, et al. Sjogren's syndrome: autoimmune epithelitis. Adv Exp Med Biol 1999; 455: 127-34
7. McArthur C, Wang Y, Veno P, et al. Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol 2002 Jun; 47 (6): 443-8
8. Venables PJ, Rugby SP. Viruses in the etiopathogenesis of Sjogren's syndrome. J Rheumatol Suppl 1997 Sep; 50: 3-5
9. Sawalha AH, Potts R, Schmid WR, et al. The genetics of primary Sjogren's syndrome. Curr Rheumatol Rep 2003 Aug; 5 (4): 324-32
10. Manthorpe R, Oxholm P, Prause JU, et al. The Copenhagen criteria for Sjogren's syndrome. Scand J Rheumatol Suppl 1986; 61: 19-21
11. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993 Mar; 36 (3): 340-7
12. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 Jun; 61 (6): 554-8
13. Price EJ, Venables PJ. Dry eyes and mouth syndrome: a subgroup of patients presenting with sicca symptoms. Rheumatology (Oxford) 2002 Apr; 41 (4): 416-22
14. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999 Jun 28; 159 (12): 1359-63
15. Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. Salisbury Eye Evaluation. J Rheumatol 1998 Mar; 25 (3): 486-91
16. Hermann GA, Vivino FB, Goin JE. Scintigraphic features of chronic sialadenitis and Sjogren's syndrome: a comparison. Nucl Med Commun 1999 Dec; 20 (12): 1123-32
17. Kalk WW, Vissink A, Spijkervet FK, et al. Morbidity from parotid sialography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 Nov; 92 (5): 572-5
18. Kalk WW, Vissink A, Spijkervet FK, et al. Parotid sialography for diagnosing Sjogren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002 Jul; 94 (1): 131-7
19. Radfar L, Kleiner DE, Fox PC, et al. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 2002 Oct 15; 47 (5): 520-4
20. Xu KP, Katagiri S, Takeuchi T, et al. Biopsy of labial salivary glands and lacrimal glands in the diagnosis of Sjogren's syndrome. J Rheumatol 1996 Jan; 23 (1): 76-82
21. de Wilde PC, Baak JP, Slootweg PJ, et al. Morphometry in the diagnosis of Sjogren's syndrome. Anal Quant Cytol Histol 1986 Mar; 8 (1): 49-55
22. Pennec YL, Leroy JP, Jouquan J, et al. Comparison of labial and sublingual salivary gland biopsies in the diagnosis of Sjogren's syndrome. Ann Rheum Dis 1990 Jan; 49 (1): 37-9
23. Fox PC. Simplified biopsy technique for labial minor salivary glands. Plast Reconstr Surg 1985 Apr; 75 (4): 592-3
24. Daniels TE. Labial salivary gland biopsy in Sjogren's syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984 Feb; 27 (2): 147-56
25. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjogren's disease. J Clin Pathol 1968 Sep; 21 (5): 656-60
26. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: analysis of 618 patients with suspected Sjogren's syndrome. Arthritis Rheum 1994 Jun; 37 (6): 869-77
27. Greenspan JS, Daniels TE, Talal N, et al. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974 Feb; 37 (2): 217-29
28. Kikuchi M, Inagaki T, Ogawa K, et al. Histopathological investigation of salivary glands in the asymptomatic elderly. Arch Gerontol Geriatr 2004 Mar-Apr; 38 (2): 131-8
29. Larsson A, Bredberg A, Henriksson G, et al. Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjogren's syndrome and healthy subjects. Scand J Immunol 2005 Jan; 61 (1): 98-107
30. Adamson 3rd TC, Fox RI, Frisman DM, et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol 1983 Jan; 130 (1): 203-8
31. Manthorpe R, Benoni C, Jacobsson L, et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients: can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjogren's syndrome? Ann Rheum Dis 2000 Jan; 59 (1): 54-60
32. Morimoto Y, Habu M, Tomoyose T, et al. Dynamic magnetic resonance sialography as a new diagnostic technique for patients with Sjogren's syndrome. Oral Dis 2006 Jul; 12 (4): 408-14
33. Hocevar A, Ambrozic A, Rozman B, et al. Ultrasonographic changes of major salivary glands in primary Sjogren's syndrome: diagnostic value of a novel scoring system. Rheumatology 2005 Jun; 44 (6): 768-72
34. Niemela RK, Takalo R, Paakko E, et al. Ultrasonography of salivary glands in primary Sjogren's syndrome: a comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. Rheumatology 2004 Jul; 43 (7): 875-9
35. Manoussakis MN, Tzioufas AG, Silis MP, et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987 Sep; 69 (3): 557-65
36. Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjogren's syndrome. Scand J Rheumatol 1999; 28 (4): 227-32
37. Tishler M, Yaron I, Shirazi I, et al. Clinical and immunological characteristics of elderly onset Sjogren's syndrome: a comparison with younger onset disease. J Rheumatol 2001 Apr; 28 (4): 795-7
38. Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjogren's syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8 (1): 20-3
39. Asmussen K, Andersen V, Bendicen G, et al. A new model for classification of disease manifestations in primary Sjogren's syndrome: evaluation in a retrospective long term study. J Int Med 1996 Jun; 239 (6): 475-82
40. Daniels TE, Silverman Jr S, Michalski JP, et al. The oral component of Sjogren's syndrome. Oral Surg 1975 Jun; 39 (6): 875-85
41. Fox RI. Clinical features, pathogenesis, and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1996 Sep; 8 (5): 438-45
42. Freeman SR, Sheehan PZ, Thorpe MA, et al. Ear, nose, and throat manifestations of Sjogren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005 Feb; 34 (1): 20-4
43. Haga HJ, Gjesdal CG, Irgens LM, et al. Reproduction and gynaecological manifestations in women with primary Sjogren's syndrome: a case-control study. Scand J Rheumatol 2005; 34 (1): 45-8
44. Wright SA, Convery RP, Liggett N. Pulmonary involvement in Sjogren's syndrome. Rheumatology (Oxford) 2003 May; 42: 697-8
45. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006 Nov; 130 (5): 1489-95
46. Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjogren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999 Jan; 58 (1): 61-4
47. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren's syndrome. Ann Rheum Dis 2000 Sep; 59 (9): 709-12
48. Soy M, Piskin S. Cutaneous findings in patients with primary Sjogren's syndrome. Clin Rheumatol 2006; 26 (8): 1350-2
49. Bernacchi E, Amato L, Parodi A, et al. Sjogren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004 Jan-Feb; 22 (1): 55-62
50. Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004 Mar; 83 (2): 96-106
51. Pease CT, Shattles W, Barrett NK, et al. The arthropathy of Sjogren's syndrome. Br J Rheumatol 1993 Jul; 32 (7): 609-13
52. Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005 Jan; 64 (1): 114-7
53. Ostuni P, Botsios C, Sfriso P, et al. Fibromyalgia in Italian patients with primary Sjogren's syndrome. Joint Bone Spine 2002 Jan; 69 (1): 51-7
54. Giles I, Isenberg D. Fatigue in primary Sjogren's syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis 2000 Nov; 59 (11): 875-8
55. Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sjogren's syndrome and is not related to muscle pain. J Rheumatol 2002 Apr; 29 (4): 717-25
56. Binder A, Snaith ML, Isenberg D. Sjogren's syndrome: a study of its neurological complications. Br J Rheumatol 1988 Aug; 27 (4): 275-80
57. Govoni M, Padovan M, Rizzo N, et al. Neurological involvement in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001; 15 (8): 597-607
58. Lafitte C, Amoura Z, Cacoub P, et al. Neurological complications of primary Sjogren's syndrome. J Neurol 2001 Jul; 248 (7): 577-84
59. Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjogren syndrome: a population-based study. Arch Neurol 2006 Nov; 63 (11): 1612-5
60. Lopate G, Pestronk A, Al-Lozi M, et al. Peripheral neuropathy in an outpatient cohort of patients with Sjogren's syndrome. Muscle Nerve 2006 May; 33 (5): 672-6
61. Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, et al. Involvement of the peripheral nervous system in primary Sjogren's syndrome. Ann Rheum Dis 2001 Sep; 60 (9): 876-81
62. Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sjogren's syndrome: a controlled study. J Rheumatol 1998 Dec; 25 (12): 2385-8
63. Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle: a clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993 Nov; 19 (4): 869-908
64. Coates T, Slavotinek JP, Rischmueller M, et al. Cerebral white matter lesions in primary Sjogren's syndrome: a controlled study. J Rheumatol 1999 Jun; 26 (6): 1301-5
65. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001 Jan; 70 (1): 9-14
66. Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. Nephrol Dial Transplant 2001 Dec; 16 (12): 2328-36
67. Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore) 2000 Jul; 79 (4): 241-9
68. Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitis-like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. Am J Med 2003 Jul; 115 (1): 62-5
69. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993 Sep 4; 342 (8871): 575-7
70. Raderer M, Osterreicher C, Machold K, et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 2001 Jul; 12 (7): 937-9
71. Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjogren's syndrome: a retrospective review. BMC Gastroenterol 2002 Sep 13; 2: 21
72. Miller EB, Shichmanter R, Friedman JA, et al. Granulomatous hepatitis and Sjogren's syndrome: an association. Semin Arthritis Rheum 2006 Dec; 36 (3): 153-8
73. Reichlin M. Antibodies to Ro and La. Ann Med Interne (Paris) 1998 Feb; 149 (1): 34-41
74. Ramos-Casals M, Nardi N, Brito-Zeron P, et al. Atypical auto-antibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006 Apr; 35 (5): 312-21
75. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 2002 Jul; 81 (4): 281-92
76. Stewart A, Blenkinsopp PT, Henry K. Bilateral parotid MALT lymphoma and Sjogren's syndrome. Br J Oral Maxillofac Surg 1994 Oct; 32 (5): 318-22
77. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978 Dec; 89 (6): 888-92
78. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006 Jun; 65 (6): 796-803
79. Lazarus M, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rhematology 2006; 45: 1012-5
80. Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999 Aug; 42 (8): 1765-72
81. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006 Mar; 18 (2): 129-34
82. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002 Mar; 46 (3): 741-7
83. Anaya JM, Tobon GJ, Vega P, et al. Autoimmune disease aggregation in families with primary Sjogren's syndrome. J Rheum 2006 Nov; 33 (11): 2227-34
84. Lazarus M, Isenberg D. Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis 2005 Jul; 64: 1062-4
85. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999 Jan 25; 159 (2): 174-81
86. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003 Dec; 62 (12): 1204-7
87. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002 Mar; 46 (3): 748-54
88. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 2002 Jun 10; 162 (11): 1293-300
89. Cummins M, Papas A, Kammer G, et al. Treatment of primary Sjogren's syndrome with low dose human interferon alpha administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49 (4): 585-93
90. Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996 Jun; 5 Suppl. 1: S31-6
91. Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double-blind crossover trial. Ann Rheum Dis 1993 May; 52 (5): 360-4
92. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 1996 Sep-Oct; 14 (5): 555-8
93. Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 1998 May; 25 (5): 896-9
94. Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporin A therapy in patients with primary Sjogren's syndrome: results at one year. Scand J Rheumatol Suppl 1986; 61: 246-9
95. Kizawa M, Mori K, Iijima M, et al. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 2006 Aug; 77 (8): 967-9
96. de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to Sjogren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol 2006 Apr; 33 (4): 709-11
97. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004 Sep; 83 (5): 280-91
98. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Intern Med 1999 Dec; 38 (12): 938-43
99. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004 Jul; 50 (7): 2240-5
100. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004 Apr; 50 (4): 1270-6
101. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005 Sep; 52 (9): 2740-50
102. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8 (4): R129
103. Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients. Eye 2005 May; 19 (5): 535-9
104. Marsh P, Pflugfelder SC. Topical nonpreserved methyl-prednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999 Apr; 106 (4): 811-6
105. Hong S, Kim T, Chung S, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. J Ocul Pharm Therapeut 2007; 23: 78-82
106. Sall K, Stevenson O, Mondorf T, et al. Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eyes: CsA Phase 3 Study Group. Ophthalmology 2000 Apr; 107 (4): 631-9
107. Tatlipinar S, Akpek E. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005 Oct; 89 (10): 1363-7
108. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh) 1994 Aug; 72 (4): 438-42
109. Al-Hashimi I. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Drugs Aging 2005; 22 (11): 887-99
110. van der Reijden WA, van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjogren's syndrome. Arthritis Rheum 1996 Jan; 39 (1): 57-63
111. Mulherin D, Ainsworth JR, Hamburger J, et al. Survey of artificial tear and saliva usage among patients with Sjogren's syndrome [letter]. Ann Rheum Dis 2001 Nov; 60 (11): 1077
112. Venables PJ. Management of patients presenting with Sjogren' syndrome. Best Pract Res Clin Rheumatol 2006 Aug; 20 (4): 791-807
113. Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 Jan; 95 (1): 38-44
114. Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999 Aug; 19 (8): 943-51
115. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998 Apr; 18 (4): 255-62
116. Ferraccioli GF, Salaffi F, De Vita S, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients: preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996 Jul-Aug; 14 (4): 367-71
117. Kastrup O, Maschke M, Diener HC. Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome. Clin Neurol Neurosurg 2005 Aug; 107 (5): 440-1
118. Levy Y, Uziel Y, Zandman G, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003 Dec; 62 (12): 1221-3
119. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001 Oct; 44 (10): 2371-5
120. Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006 Aug; 65 (8): 1033-7